Arvinas Inc.

77 articles with Arvinas Inc.

• Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

  11/19/2021

  Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471 will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021.

• 

  Avilar Debuts to Pioneer Extracellular Protein Degradation

  11/18/2021

  Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.

• Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

  11/10/2021

  Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 10:40 a.m. ET.

• Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/3/2021

  Arvinas, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Arvinas to Participate in Upcoming Virtual Investor Conferences in September 2021

  9/1/2021

  Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that it will participate in two upcoming virtual investor conferences:

• Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

  7/22/2021

  Arvinas, Inc. and Pfizer Inc. today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.

• Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

  6/7/2021

  Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven’s Downtown Crossing revitalization project.

• Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference

  6/3/2021

  Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET.

• Arvinas to Present at the UBS Global Healthcare Virtual Conference

  5/20/2021

  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET.

• Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/4/2021

  Arvinas, Inc., a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

• Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

  4/5/2021

  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021.

• Arvinas to Participate in Upcoming Virtual Investor Conferences - Mar 10, 2021

  3/10/2021

  Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that it will participate in two upcoming virtual investor conferences.

• Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/1/2021

  Arvinas, Inc., a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

• Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

  2/8/2021

  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET.

• Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

  12/28/2020

  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on December 18, 2020, have exercised in full their option to purchase additional shares of common stock at the public offering price, less underwr

• Arvinas, Inc. Announced Proposed Offering of Common Stock

  12/14/2020

  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced that it is commencing an underwritten public offering of $250.0 million of its common stock. In addition, Arvinas intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $37.5 million of its common stock. The of

• Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs

  12/11/2020

  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to provide clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. The presentation will include upda

• Arvinas to Participate in Upcoming Virtual Investor Conferences

  11/25/2020

  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference  on Tuesday, December 1, 2020. A pre-recorded fireside chat held with John Houston, Ph.D., President and Chief Executive Officer, and Ian Taylor, Ph.D., C

• Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/5/2020

  – First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues ; program updates planned for December 2020 – – Arvinas and Pfizer enter collaboration and supply agreement ; initiation of Phase 1b combination of ARV-471 and Ibrance ® e xpected in the f ourth q uarter of 2020 –